Cargando…

Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence

BACKGROUND: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. METHODS: A total of 89 patients treated for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zouhry, Yacine, Taibi, Abdelkader, Durand-Fontanier, Sylvaine, Darbas, Tiffany, Forestier, Geraud, Monteil, Jacques, Lebrun-Ly, Valérie, Fayemendy, Philippe, Leobon, Sophie, Jesus, Pierre, Deluche, Elise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653570/
https://www.ncbi.nlm.nih.gov/pubmed/34876055
http://dx.doi.org/10.1186/s12885-021-09037-3
_version_ 1784611692358926336
author Zouhry, Yacine
Taibi, Abdelkader
Durand-Fontanier, Sylvaine
Darbas, Tiffany
Forestier, Geraud
Monteil, Jacques
Lebrun-Ly, Valérie
Fayemendy, Philippe
Leobon, Sophie
Jesus, Pierre
Deluche, Elise
author_facet Zouhry, Yacine
Taibi, Abdelkader
Durand-Fontanier, Sylvaine
Darbas, Tiffany
Forestier, Geraud
Monteil, Jacques
Lebrun-Ly, Valérie
Fayemendy, Philippe
Leobon, Sophie
Jesus, Pierre
Deluche, Elise
author_sort Zouhry, Yacine
collection PubMed
description BACKGROUND: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. METHODS: A total of 89 patients treated for LAE cancer between January 2009 and December 2019 were included in this study. Computed tomography (CT) scans before treatment and at recurrence were evaluated. SMI and other body composition parameters were analysed by the L3 scan method. RESULTS: Participants were aged 66.0 (36.0–86) years. The incidence of low SMI increased by 12.3% between diagnosis and recurrence (70.7% vs. 83.0%, respectively) over a median follow-up of 16.9 (1.7–101.6) months. Patients with high SMI at diagnosis showed loss of muscle mass (58.0 vs. 55.2 cm(2)/m(2), respectively; P < 0.001) and decreased body mass index (BMI) (27.9 vs. 26.3 kg/m(2), respectively; P = 0.05), but fat mass was increased (68.9 vs. 72.0 cm(2)/m(2), respectively; P = 0.01). Patients with low SMI at diagnosis showed no significant changes in body composition parameters and no improvement of SMI, even with nutritional support. Low SMI (hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.02–3.16) was an independent predictor (P = 0.041) of high nutritional risk index (HR: 1.79; 95% CI: 1.03–3.11; P = 0.039) at diagnosis. CONCLUSIONS: The percentage of patients with a low SMI increased during follow-up. Our data suggest that an assessment of skeletal muscle parameters and nutrition support may be more useful in patients with a high SMI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09037-3.
format Online
Article
Text
id pubmed-8653570
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86535702021-12-08 Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence Zouhry, Yacine Taibi, Abdelkader Durand-Fontanier, Sylvaine Darbas, Tiffany Forestier, Geraud Monteil, Jacques Lebrun-Ly, Valérie Fayemendy, Philippe Leobon, Sophie Jesus, Pierre Deluche, Elise BMC Cancer Research BACKGROUND: The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. METHODS: A total of 89 patients treated for LAE cancer between January 2009 and December 2019 were included in this study. Computed tomography (CT) scans before treatment and at recurrence were evaluated. SMI and other body composition parameters were analysed by the L3 scan method. RESULTS: Participants were aged 66.0 (36.0–86) years. The incidence of low SMI increased by 12.3% between diagnosis and recurrence (70.7% vs. 83.0%, respectively) over a median follow-up of 16.9 (1.7–101.6) months. Patients with high SMI at diagnosis showed loss of muscle mass (58.0 vs. 55.2 cm(2)/m(2), respectively; P < 0.001) and decreased body mass index (BMI) (27.9 vs. 26.3 kg/m(2), respectively; P = 0.05), but fat mass was increased (68.9 vs. 72.0 cm(2)/m(2), respectively; P = 0.01). Patients with low SMI at diagnosis showed no significant changes in body composition parameters and no improvement of SMI, even with nutritional support. Low SMI (hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.02–3.16) was an independent predictor (P = 0.041) of high nutritional risk index (HR: 1.79; 95% CI: 1.03–3.11; P = 0.039) at diagnosis. CONCLUSIONS: The percentage of patients with a low SMI increased during follow-up. Our data suggest that an assessment of skeletal muscle parameters and nutrition support may be more useful in patients with a high SMI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-09037-3. BioMed Central 2021-12-07 /pmc/articles/PMC8653570/ /pubmed/34876055 http://dx.doi.org/10.1186/s12885-021-09037-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zouhry, Yacine
Taibi, Abdelkader
Durand-Fontanier, Sylvaine
Darbas, Tiffany
Forestier, Geraud
Monteil, Jacques
Lebrun-Ly, Valérie
Fayemendy, Philippe
Leobon, Sophie
Jesus, Pierre
Deluche, Elise
Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
title Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
title_full Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
title_fullStr Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
title_full_unstemmed Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
title_short Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
title_sort degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653570/
https://www.ncbi.nlm.nih.gov/pubmed/34876055
http://dx.doi.org/10.1186/s12885-021-09037-3
work_keys_str_mv AT zouhryyacine degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT taibiabdelkader degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT durandfontaniersylvaine degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT darbastiffany degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT forestiergeraud degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT monteiljacques degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT lebrunlyvalerie degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT fayemendyphilippe degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT leobonsophie degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT jesuspierre degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence
AT delucheelise degradationofskeletalmassinlocallyadvancedoesophagealcancerbetweeninitialdiagnosisandrecurrence